Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HCK | P08631 | 1/20 | 0.59 |
| ▸ | FGR | P09769 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.59 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179050 | 0.87 | RET (0.75) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL30381942 | 0.87 | RET (0.75) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21191306 | 0.85 | RET (1.00) | RET | |
| SCHEMBL21179088 | 0.85 | RET (0.73) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178657 | 0.85 | RET (0.59) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178700 | 0.84 | RET (0.61) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL31639783 | 0.84 | RET (0.59) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21179057 | 0.83 | RET (0.72) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21191361 | 0.83 | RET (1.00) | RET | |
| SCHEMBL29909576 | 0.83 | RET (1.00) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20200399279-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399279-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-12-24 | — | — | US | disclosed |
| EP-3740490-A1 | SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-111630054-A | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019143991-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143991-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399279-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885CYP1A2 3823/4885HCK 837/4885 |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885CYP1A2 3721/4885HCK 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.